Paolo Bucciarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7601177/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	1.2	1
2	Genomeâ€Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis. Annals of Neurology, 2021, 90, 777-788.	2.8	10
3	Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Seminars in Thrombosis and Hemostasis, 2019, 45, 036-042.	1.5	15
4	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 808-814.	0.7	43
5	Thrombophilic and cardiovascular risk factors for retinal vein occlusion. European Journal of Internal Medicine, 2017, 44, 44-48.	1.0	27
6	Red cell distribution width and the risk of cerebral vein thrombosis: A case–control study. European Journal of Internal Medicine, 2017, 38, 46-51.	1.0	15
7	Increased risk of venous thromboembolism in patients with bullous pemphigoid. Thrombosis and Haemostasis, 2016, 115, 193-199.	1.8	30
8	Baseline factor <scp>VIII</scp> plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia, 2016, 22, 564-569.	1.0	4
9	Towards the genetic basis of cerebral venous thrombosis—the BEAST Consortium: a study protocol: TableÂ1. BMJ Open, 2016, 6, e012351.	0.8	23
10	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thrombosis Research, 2016, 141, 153-157.	0.8	11
11	Pregnancy outcome after a first episode of cerebral vein thrombosis. Journal of Thrombosis and Haemostasis, 2016, 14, 2386-2393.	1.9	15
12	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. Journal of Thrombosis and Haemostasis, 2015, 13, 1806-1814.	1.9	11
13	Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case–Control Studies. PLoS Medicine, 2015, 12, e1001899.	3.9	35
14	Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS ONE, 2015, 10, e0129456.	1.1	28
15	Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome. Thrombosis Research, 2015, 135, 508-512.	0.8	54
16	The "Pregnancy Health-care Program―for the prevention of venous thromboembolism in pregnancy. Internal and Emergency Medicine, 2015, 10, 129-134.	1.0	20
17	Association between red cell distribution width and risk of venous thromboembolism. Thrombosis Research, 2015, 136, 590-594.	0.8	34
18	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. Journal of Thrombosis and Haemostasis, 2015, 13, 228-236.	1.9	18

#	Article	IF	CITATIONS
19	Cerebral Thrombosis and Myeloproliferative Neoplasms. Current Neurology and Neuroscience Reports, 2014, 14, 496.	2.0	32
20	Hemostatic Abnormalities in Noonan Syndrome. Pediatrics, 2014, 133, e1299-e1304.	1.0	49
21	Thrombophilic states. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 1061-1071.	1.0	19
22	Pulmonary embolism in elderly patients: Prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. Thrombosis Research, 2014, 134, 326-330.	0.8	19
23	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	0.6	123
24	Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. Thrombosis Research, 2013, 132, e152-e157.	0.8	29
25	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. Pediatrics, 2013, 132, e1435-e1439.	1.0	33
26	High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2013, 139, 380-387.	0.4	10
27	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood, 2013, 122, 2555-2561.	0.6	9
28	Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and TromsÃ, Journal of Thrombosis and Haemostasis, 2012, 10, 1704-1707.	1.9	18
29	Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. Journal of Thrombosis and Haemostasis, 2012, 10, 1783-1791.	1.9	63
30	Circulating microparticles and risk of venous thromboembolism. Thrombosis Research, 2012, 129, 591-597.	0.8	92
31	Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women. Thrombosis Research, 2012, 129, e1-e7.	0.8	64
32	The JAK2ÂV617F mutation in patients with cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 998-1003.	1.9	61
33	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 2012, 10, 1451-1453.	1.9	24
34	Hematological evaluation of acquired von Willebrand syndrome before oral surgery: Management of an unusual case. Asian Journal of Transfusion Science, 2012, 6, 46.	0.1	0
35	Coagulation testing before epidural analgesia at delivery: Cost analysis. Thrombosis Research, 2011, 128, 18-20.	0.8	20
36	Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. American Journal of Hematology, 2011, 86, 650-656.	2.0	20

#	Article	IF	CITATIONS
37	Management of Inherited <scp>v</scp> on Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients. Seminars in Thrombosis and Hemostasis, 2011, 37, 511-521.	1.5	48
38	Risk factors for venous and arterial thrombosis. Blood Transfusion, 2011, 9, 120-38.	0.3	294
39	Thrombotic risk factors: Basic pathophysiology. Critical Care Medicine, 2010, 38, S3-S9.	0.4	126
40	Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinusâ€venous thrombosis. European Journal of Neurology, 2010, 17, 1482-1485.	1.7	4
41	Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis. Circulation, 2010, 121, 2740-2746.	1.6	120
42	The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. European Journal of Internal Medicine, 2010, 21, 301-305.	1.0	42
43	Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII. Thrombosis Research, 2010, 126, 243-245.	0.8	12
44	Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. British Journal of Haematology, 2009, 144, 803-805.	1.2	15
45	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. Journal of Hepatology, 2009, 50, 916-922.	1.8	69
46	The hemostatic system through aging and menopause. Climacteric, 2009, 12, 47-51.	1.1	30
47	Aging, menopause, cardiovascular disease and HRT. Climacteric, 2009, 12, 368-377.	1.1	35
48	Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood, 2009, 113, 526-534.	0.6	239
49	High-d-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Digestive and Liver Disease, 2008, 40, 874-881.	0.4	23
50	VEGF Expression Correlates With Microvessel Density in Philadelphia Chromosome–Negative Chronic Myeloproliferative Disorders. American Journal of Clinical Pathology, 2007, 128, 966-973.	0.4	48
51	Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma. Thrombosis Research, 2007, 120, 289-293.	0.8	12
52	Reply:. Hepatology, 2007, 45, 832-833.	3.6	1
53	Usefulness of PFAâ€100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. Journal of Thrombosis and Haemostasis, 2007, 5, 2393-2398.	1.9	99
54	Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients Blood, 2007, 110, 713-713.	0.6	6

#	Article	IF	CITATIONS
55	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. Supportive Cancer Therapy, 2006, 3, 98-102.	0.3	15
56	Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. Thrombosis and Haemostasis, 2006, 95, 909-910.	1.8	21
57	Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood, 2006, 107, 1731-1731.	0.6	73
58	New approaches for measuring coagulation. Haemophilia, 2006, 12, 76-81.	1.0	52
59	Psychological impact of thrombosis in the young. Internal and Emergency Medicine, 2006, 1, 119-126.	1.0	8
60	Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44, 1528-1534.	3.6	249
61	Low levels of protein Z and the risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2005, 3, 2817-2819.	1.9	32
62	Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology, 2005, 41, 603-608.	3.6	190
63	Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study. Human Mutation, 2005, 25, 259-269.	1.1	48
64	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Annals of Oncology, 2004, 15, 590-593.	0.6	52
65	Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis. Circulation, 2004, 109, 740-744.	1.6	60
66	Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities. Circulation, 2004, 110, 566-570.	1.6	172
67	Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiology of Aging, 2004, 25, 1009-1015.	1.5	131
68	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 2004, 104, 3631-3634.	0.6	179
69	Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thrombosis Research, 2003, 112, 37-41.	0.8	56
70	Reply to a Rebuttal: Counseling Pregnant Women Homozygous for Factor V Leiden. Thrombosis and Haemostasis, 2002, 87, 361-361.	1.8	0
71	Low risk of thrombosis in family members of patients with hyperhomocysteinaemia. British Journal of Haematology, 2002, 117, 709-711.	1.2	6
72	Identification of Four Novel Polymorphisms in the Aα and γ Fibrinogen Genes and Analysis of Association with Plasma Levels of the Protein. Thrombosis Research, 2001, 103, 299-307.	0.8	11

#	Article	IF	CITATIONS
73	A 23bp Insertion in the Endothelial Protein C Receptor (EPCR) Gene Impairs EPCR Function. Thrombosis and Haemostasis, 2001, 86, 945-948.	1.8	56
74	Risk of Pregnancy-related Venous Thrombosis in Carriers of Severe Inherited Thrombophilia. Thrombosis and Haemostasis, 2001, 86, 800-803.	1.8	119
75	Probability Density Estimation Using Adaptive Activation Function Neurons. Neural Processing Letters, 2001, 13, 31-42.	2.0	19
76	Low Plasma Levels of Vitamin B ₆ Are Independently Associated With a Heightened Risk of Deep-Vein Thrombosis. Circulation, 2001, 104, 2442-2446.	1.6	67
77	Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. European Journal of Endocrinology, 2001, 145, R1-R4.	1.9	14
78	Acquired von Willebrand Syndrome: Data from an International Registry. Thrombosis and Haemostasis, 2000, 84, 345-349.	1.8	327
79	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	1.2	6
80	Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental and Clinical Endocrinology and Diabetes, 2000, 108, 486-492.	0.6	35
81	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	1.2	89
82	Interaction Between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 700-703.	1.1	170
83	Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1026-1033.	1.1	145
84	Fibrinogen Milano XIII (Aα 19 Arg→Gly). Thrombosis Research, 1999, 96, 399-405.	0.8	6
85	Budd-Chiari Syndrome in a Patient Heterozygous for the G20210A Mutation of the Prothrombin Gene. Thrombosis and Haemostasis, 1998, 79, 445-446.	1.8	26
86	Occult Cancer and Venous Thromboembolism. Thrombosis and Haemostasis, 1998, 80, 347-348.	1.8	0
87	A Common Mutation in the Methylenetetrahydrofolate Reductase Gene (C677T) Increases the Risk for Deep-Vein Thrombosis in Patients With Mutant Factor V (Factor V:Q 506). Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1662-1666.	1.1	161